首页> 美国卫生研究院文献>other >Heparan sulfate/heparin glycosaminoglycan binding alters inhibitory profile and enhances anticoagulant function of conserved Amblyomma americanum tick saliva serpin 19
【2h】

Heparan sulfate/heparin glycosaminoglycan binding alters inhibitory profile and enhances anticoagulant function of conserved Amblyomma americanum tick saliva serpin 19

机译:硫酸乙酰肝素/肝素糖胺聚糖结合物改变抑制谱并增强保守的美洲american滴虫唾液丝氨酸蛋白酶抑制剂19的抗凝功能

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Some serine protease inhibitor (serpin) regulators of essential life pathways bind glycosaminoglycans (GAGs) to enhance inhibitory functions and achieve physiologically relevant rates. This study demonstrates that highly conserved Amblyomma americanum tick saliva serpin 19 (AAS19), a broad-spectrum inhibitor of hemostasis and inflammation system proteases and anticoagulant, can bind heparan sulfate/heparin (HS)GAGs and that this interaction alters its function. Substrate hydrolysis and unpaired t-test analyses revealed that HSGAG binding caused rAAS19 inhibitory activity to: (i) significantly increase against blood clotting factors (f) IIa (thrombin) and fIXa, (ii) significantly reduce against fXa and fXIIa and (iii) moderate to no effect against trypsin, kallikrein, papain, and plasmin. Stoichiometry of inhibition (SI) analyses show that HSGAG binding improved the rAAS19 inhibitory efficiency against thrombin 2.7-4.3 folds as revealed by SI of 13.19 in absence of HSGAGs to 4.83-3.04 in their presence. Our data show that HSGAG binding dramatically enhanced rAAS19 anticoagulant function. In the recalcification time assay, rAAS19 pre-incubated with HSGAGs prior to the assay, delayed plasma clotting by an additional 176-457 s above HSGAGs or rAAS19 alone. Our data suggest that formation of the HSGAGs and rAAS19 complex is important for the observed enhanced anticoagulant effect. Delay of plasma clotting was higher when HSGAGs and rAAS19 were co-incubated to allow complex formation prior to blood clotting assay as opposed to no co-incubation. We have discussed our finding with reference to tick feeding physiology and utility of the rAAS19 in blood clotting disorder therapy.
机译:一些必需的生命途径的丝氨酸蛋白酶抑制剂(serpin)调节剂结合糖胺聚糖(GAGs)来增强抑制功能并达到生理相关的速率。这项研究表明,高度保守的美洲and唾液丝氨酸蛋白酶抑制剂19(AAS19)是止血和炎症系统蛋白酶和抗凝剂的广谱抑制剂,可以结合硫酸乙酰肝素/肝素(HS)GAG,并且这种相互作用会改变其功能。底物水解和未配对的t检验分析表明,HSGAG结合导致rAAS19抑制活性为:(i)抗凝血因子显着增加(f)IIa(凝血酶)和fIXa,(ii)抗fXa和fXIIa显着降低,以及(iii)对胰蛋白酶,激肽释放酶,木瓜蛋白酶和纤溶酶的影响中等至没有影响。抑制化学计量(SI)分析表明,如不存在HSGAG的13.19的SI显示,HSGAG结合可提高rAAS19对凝血酶的抑制效率2.7-4.3倍至存在它们的4.83-3.04。我们的数据表明,HSGAG结合显着增强了rAAS19的抗凝功能。在重新钙化时间测定中,在测定之前将rAAS19与HSGAGs预孵育,比单独的HSGAGs或rAAS19高176-457 s延迟血浆凝结。我们的数据表明,HSGAG和rAAS19复合物的形成对于观察到的增强抗凝作用很重要。与不进行共孵育相比,将HSGAG和rAAS19共孵育以允许在血液凝结测定之前形成复合物时,血浆凝块的延迟较高。我们已经讨论了我们的发现,并参考了tick喂养生理和rAAS19在凝血障碍治疗中的实用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号